NGS technologies can detect driver mutations in cancer, including in the genes involved in the homologous recombination (HR) DNA repair pathway, such as BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATM, CHEK2, BARD1, CDK12, and others. This evidence concerns the gene BRCA2 and cancer.